



**ANADYS PHARMACEUTICALS TO PRESENT  
AT THE CANACCORD ADAMS HEPATITIS C CONFERENCE**

**SAN DIEGO, March 25, 2010** -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the CanAccord Adams Hepatitis C Conference on Thursday, April 1, 2010 at 1:30 p.m. EDT (10:30 a.m. PDT). The conference is being held at the Peninsula Hotel in New York. Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, ANA598 and ANA773.

The corporate presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at [www.anadyspharma.com](http://www.anadyspharma.com). Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through April 15, 2010.

**About Anadys**

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.

**Safe Harbor Statement**

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2009. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

**Investor Contact:**

Amy Conrad  
Anadys Pharmaceuticals, Inc.  
(858) 530-3607  
[aconrad@anadyspharma.com](mailto:aconrad@anadyspharma.com)

**Media Contact:**

Ian Stone or David Schull  
Russo Partners, LLC  
(619) 528-2220  
[ian.stone@russopartnersllc.com](mailto:ian.stone@russopartnersllc.com)  
[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)